Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee.
Central to our current understanding of heart failure is the concept that compensatory mechanisms that maintain blood pressure and perfusion ultimately contribute to worsening of ventricular function. Studies of the effect of angiotensin-converting enzyme inhibitors in patients with heart failure are consistent with this paradigm. This manuscript describes a 2,800-patient randomized trial that will definitively determine whether sympathetic nervous system antagonism with a beta blocker prolongs the life of patients with moderate to severe heart failure.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D011412:Propanolamines / Q000627:therapeutic use*; D012107:Research Design; D015996:Survival Rate
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C024307:bucindolol